Skip to main
PRTA

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Prothena Corp has demonstrated encouraging clinical results in reducing amyloid levels for its investigational therapies, particularly at the 200mg and 400mg dose levels, which is significant for the treatment of neurodegenerative diseases. The company has projected potential earnings of up to $105 million, approximately $2 per basic share outstanding, from development milestones related to its partnerships with Novo Nordisk and Bristol-Myers Squibb by 2026. Additionally, despite some concerns regarding elevated ARIA incidence in one of its treatments, PRX012 has shown overall favorable tolerability with low incidence of injection-site reactions, reinforcing a generally positive outlook on the company’s development pipeline.

Bears say

Prothena Corp PLC faces a negative outlook due to its continued net losses, which are expected to persist until product approval or commercialization, indicating significant financial strain in the near term. The company may need to raise additional capital to support the development of its drug candidates, which poses a risk of dilution to existing shareholders and adds uncertainty regarding future shareholder value. Moreover, potential changes in regulatory stances could introduce obstacles to product approvals, further complicating the company's financial position and its ability to generate revenue.

Prothena (PRTA) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 8 analysts, Prothena (PRTA) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.